Impact of NR3C1 rs41423247 (BclI) Polymorphism on Disease Severity in Alopecia Areata

NCT07455708 | Completed

• 2 other identifiers: Ms 10.9.2023Benha faulty of medicine
• Study Type: observational
• Target: 120
• Locations: 1 country
• Sites: 1

Brief Summary

Alopecia areata is an autoimmune, non-scarring hair loss disorder with multifactorial pathogenesis. The glucocorticoid receptor gene (NR3C1) plays an essential role in immune regulation and inflammatory response. The rs41423247 polymorphism (BclI) may influence glucocorticoid sensitivity and disease activity. This study aims to investigate the association between NR3C1 rs41423247 polymorphism and susceptibility to alopecia areata and to evaluate its correlation with disease severity using the Severity of Alopecia Tool (SALT) score.

Conditions

Alopecia Areata(AA)

Keywords

Alopecia areata; Glucocorticoid; polymorphism

Outcome Measures

Primary Outcomes (1)

• Distribution of NR3C1 rs41423247 Genotypes and Alleles

  Comparison of genotype and allele frequencies of NR3C1 rs41423247 polymorphism between alopecia areata patients and healthy controls.

  Baseline

Secondary Outcomes (1)

• Association Between NR3C1 rs41423247 Polymorphism and Disease Severity

  Baseline

Study Arms (2)

Group 1: Alopecia Areata Patients

Participants diagnosed clinically with alopecia areata (n = 60). Peripheral blood samples will be collected for genetic analysis of NR3C1 rs41423247 polymorphism. Disease severity will be assessed using SALT score.

Group 2: Healthy Controls

Age- and sex-matched healthy individuals without autoimmune disease (n = 60). Peripheral blood samples will be collected for genetic analysis of NR3C1 rs41423247 polymorphism.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study will include 60 patients clinically diagnosed with alopecia areata and 60 age- and sex-matched healthy controls recruited from the same geographic area.

You may qualify if:

• Clinically diagnosed alopecia areata
• Age ≥ 18 years
• Both sexes
• Willingness to participate and provide informed consent
• Apparently healthy individuals
• No history of autoimmune disease
• Age- and sex-matched to cases
• Provided informed consent

You may not qualify if:

• Presence of other autoimmune or inflammatory diseases
• Current systemic immunosuppressive therapy
• Pregnancy or lactation
• Refusal to participate

Sponsors & Collaborators

• Benha University: lead

Study Sites (1)

Benha University

Banhā, Qalyubia Governorate, 13511, Egypt

Location

MeSH Terms

Conditions

Alopecia Areata

Condition Hierarchy (Ancestors)

Alopecia; Hypotrichosis; Hair Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Target Duration: 1 Day
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: assistant professor

Study Record Dates

• First Submitted: March 3, 2026
• First Posted: March 6, 2026
• Study Start: November 1, 2023
• Primary Completion: November 1, 2024
• Study Completion: December 1, 2024
• Last Updated: March 6, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)